That work has shown that sanguinarine and ivermectin can regulate the lncRNA-EIF4A3-mRNA axis, suggesting that they might have anti-ovarian cancer activity and that EIF4A3 may participate in the progression of ovarian cancer (36, 48). Here, EIF4A3 is linked to ovarian cancer.